X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (109) 109
index medicus (90) 90
multiple sclerosis (63) 63
crotonates - therapeutic use (62) 62
toluidines - therapeutic use (62) 62
crotonates - adverse effects (55) 55
toluidines - adverse effects (52) 52
teriflunomide (51) 51
multiple sclerosis, relapsing-remitting - drug therapy (46) 46
multiple sclerosis - drug therapy (41) 41
crotonates - administration & dosage (39) 39
toluidines - administration & dosage (39) 39
female (37) 37
clinical neurology (35) 35
pharmacology & pharmacy (35) 35
administration, oral (33) 33
double-blind (32) 32
adult (31) 31
animals (29) 29
oral teriflunomide (29) 29
leflunomide (28) 28
immunosuppressive agents - therapeutic use (25) 25
male (25) 25
crotonates - pharmacology (24) 24
dimethyl fumarate (24) 24
drug therapy (23) 23
efficacy (22) 22
toluidines - pharmacology (22) 22
treatment outcome (22) 22
middle aged (21) 21
fingolimod (19) 19
neurosciences (19) 19
disease progression (17) 17
immunologic factors - therapeutic use (17) 17
safety (17) 17
immunosuppressive agents - administration & dosage (16) 16
immunosuppressive agents - adverse effects (16) 16
neurology (16) 16
glatiramer acetate (15) 15
interferon-beta - therapeutic use (15) 15
placebo-controlled phase-3 (15) 15
trial (15) 15
alemtuzumab (14) 14
clinical trials (14) 14
fingolimod hydrochloride (14) 14
progressive multifocal leukoencephalopathy (14) 14
sphingosine - analogs & derivatives (14) 14
dimethyl fumarate - therapeutic use (13) 13
immunologic factors - adverse effects (13) 13
natalizumab (13) 13
experimental autoimmune encephalomyelitis (12) 12
fingolimod hydrochloride - therapeutic use (12) 12
placebo-controlled trial (12) 12
recurrence (12) 12
antibodies, monoclonal, humanized - therapeutic use (11) 11
care and treatment (11) 11
crotonates - pharmacokinetics (11) 11
fumarates - therapeutic use (11) 11
medicine, general & internal (11) 11
randomized controlled trials as topic (11) 11
rheumatoid-arthritis (11) 11
toluidines - pharmacokinetics (11) 11
clinical trials as topic (10) 10
crotonates - chemistry (10) 10
disease (10) 10
double-blind method (10) 10
glatiramer acetate - therapeutic use (10) 10
interferon (10) 10
magnetic resonance imaging (10) 10
analysis (9) 9
dose-response relationship, drug (9) 9
drug approval (9) 9
follow-up (9) 9
fumarates - administration & dosage (9) 9
immunologic factors - administration & dosage (9) 9
medicine & public health (9) 9
propylene glycols - administration & dosage (9) 9
propylene glycols - therapeutic use (9) 9
sphingosine - administration & dosage (9) 9
sphingosine - therapeutic use (9) 9
biological response modifiers (8) 8
fumaric-acid esters (8) 8
intramuscular interferon (8) 8
pharmacotherapy (8) 8
cladribine - therapeutic use (7) 7
drug dosages (7) 7
drugs (7) 7
interferon beta-1a (7) 7
internal medicine (7) 7
multiple-sclerosis (7) 7
natalizumab - therapeutic use (7) 7
pharmacology (7) 7
united states (7) 7
young adult (7) 7
active rheumatoid-arthritis (6) 6
agouti rat model (6) 6
bg-12 (6) 6
cladribine (6) 6
clinical trials, phase iii as topic (6) 6
disease-modifying therapies (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2018, Volume 19, Issue 5, pp. 483 - 498
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at... 
interferon beta | Multiple sclerosis | ocrelizumab | dimethylfumarate | alemtuzumab | cladribine | fingolimod | teriflunomide | glatiramer acetate | natalizumab | daclizumab | HIGH-YIELD PROCESS | CONTROLLED PHASE-3 | GRANULE CELL NEURONOPATHY | FUMARIC-ACID ESTERS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | VARICELLA-ZOSTER-VIRUS | INTERFERON-BETA THERAPY | TERM-FOLLOW-UP | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | Alemtuzumab - adverse effects | Neoplasms - etiology | Crotonates - metabolism | Alemtuzumab - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Natalizumab - adverse effects | Natalizumab - metabolism | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Toluidines - therapeutic use | Toluidines - metabolism | Toluidines - adverse effects | Fingolimod Hydrochloride - metabolism | Crotonates - therapeutic use | Glatiramer Acetate - adverse effects | Cladribine - metabolism | Interferon-beta - metabolism | Cladribine - therapeutic use | Glatiramer Acetate - therapeutic use | Multiple Sclerosis - pathology | Glatiramer Acetate - metabolism | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Cladribine - adverse effects | Crotonates - adverse effects | Alemtuzumab - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2011, Volume 365, Issue 14, pp. 1293 - 1303
Journal Article
Journal of Neurology, ISSN 0340-5354, 12/2018, Volume 265, Issue 12, pp. 2980 - 2992
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2012, Volume 166, Issue 4, pp. 1320 - 1332
BACKGROUND AND PURPOSE Translational animal models are essential in the prediction of the efficacy and side effects of new chemical entities. We have carried... 
anti‐inflammatory drugs | adjuvant‐induced arthritis | JAK | immunosuppressants | DMARD | translational research | rheumatoid arthritis | p38 MAPK | DHODH | anti-inflammatory drugs | adjuvant-induced arthritis | RHEUMATOID-ARTHRITIS | ACTIVATED PROTEIN-KINASE | EFFICACY | INTERLEUKIN-6 | POTENT | DISEASES | PATHWAY | INFLAMMATION | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | LEFLUNOMIDE | Arthritis, Experimental - drug therapy | Pyrroles - pharmacokinetics | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Half-Life | Male | Weight Loss - drug effects | Oxidoreductases Acting on CH-CH Group Donors - antagonists & inhibitors | Enzyme Inhibitors - administration & dosage | Benzamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Pyrroles - administration & dosage | Splenomegaly - etiology | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Benzamides - adverse effects | Edema - prevention & control | Enzyme Inhibitors - adverse effects | Joints - drug effects | Rats | Splenomegaly - prevention & control | Gastrointestinal Tract - drug effects | Enzyme Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Pyrimidines - pharmacokinetics | Antirheumatic Agents - pharmacokinetics | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Rats, Wistar | Antirheumatic Agents - administration & dosage | Benzamides - pharmacokinetics | Toluidines - pharmacokinetics | Toluidines - administration & dosage | Arthritis, Experimental - pathology | Dose-Response Relationship, Drug | Benzamides - therapeutic use | Enzyme Inhibitors - pharmacokinetics | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Piperidines | Crotonates - administration & dosage | Pyrroles - therapeutic use | Immunosuppressive Agents - administration & dosage | Antirheumatic Agents - therapeutic use | Arthritis, Experimental - blood | Toluidines - therapeutic use | Arthritis, Experimental - physiopathology | Pyrimidines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Toluidines - adverse effects | Leukocyte Disorders - chemically induced | Crotonates - pharmacokinetics | Janus Kinases - antagonists & inhibitors | Edema - etiology | Crotonates - therapeutic use | Animals | Joints - immunology | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Immunosuppressive Agents - adverse effects | Hypercholesterolemia - chemically induced | Crotonates - adverse effects | Arthritis | Dehydrogenases | Drug dosages | Rodents | Index Medicus | Research Papers
Journal Article
Journal Article
Pharmacological Research, ISSN 1043-6618, 06/2017, Volume 120, pp. 279 - 293
Multiple Sclerosis (MS) is a chronic pathology affecting the Central Nervous System characterized by inflammatory processes that lead to demyelination and... 
Teriflunomide | Immunogenetics | Multiple sclerosis | Fingolimod | Dimethyl fumarate | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | DE-NOVO SYNTHESIS | PLACEBO-CONTROLLED PHASE-3 | ADVERSE DRUG-REACTIONS | FUMARIC-ACID ESTERS | SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 | PHARMACOLOGY & PHARMACY | DISEASE-MODIFYING THERAPIES | NF-KAPPA-B | STEVENS-JOHNSON-SYNDROME | SIGNAL-REGULATED KINASE | Toluidines - therapeutic use | Administration, Oral | Humans | Immunosuppressive Agents - therapeutic use | Multiple Sclerosis - genetics | Toluidines - adverse effects | Toluidines - administration & dosage | Crotonates - therapeutic use | Animals | Dimethyl Fumarate - therapeutic use | Dimethyl Fumarate - adverse effects | Multiple Sclerosis - immunology | Immunosuppressive Agents - adverse effects | Crotonates - administration & dosage | Crotonates - adverse effects | Dimethyl Fumarate - administration & dosage | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Immunosuppressive Agents - administration & dosage | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - drug therapy | Drug therapy | Medical research | Pharmacogenetics | Histocompatibility antigens | HLA histocompatibility antigens | Medicine, Experimental | Development and progression | Interferon | Oral medication | Drug approval
Journal Article
Journal Article
Multiple sclerosis and related disorders, ISSN 2211-0348, 11/2017, Volume 18, p. 170
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 07/2017, Volume 11, pp. 2193 - 2207
In the therapeutic scenario of disease-modifying therapies for relapsing-remitting multiple sclerosis, the introduction of oral agents, starting in 2010 with... 
Relapsing-remitting multiple sclerosis | Efficacy | Safety | Comparison | Oral agents | CHEMISTRY, MEDICINAL | comparison | PLACEBO-CONTROLLED PHASE-3 | NO EVIDENCE | FINGOLIMOD FTY720 | efficacy | PML | relapsing-remitting multiple sclerosis | DISEASE-ACTIVITY | TERIFLUNOMIDE | oral agents | RELEASE DIMETHYL FUMARATE | safety | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PATIENT | INTEGRATED ANALYSIS | Toluidines - therapeutic use | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Toluidines - adverse effects | Toluidines - administration & dosage | Crotonates - therapeutic use | Dimethyl Fumarate - therapeutic use | Dimethyl Fumarate - adverse effects | Immunosuppressive Agents - adverse effects | Crotonates - administration & dosage | Crotonates - adverse effects | Dimethyl Fumarate - administration & dosage | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Immunosuppressive Agents - administration & dosage | Fingolimod Hydrochloride - administration & dosage | Multiple sclerosis | Pharmacology, Experimental | Fingolimod | Drug therapy | Patient outcomes | Dimethyl | Drugs | Medical research | Brain | Liver | Medical services | Health risks | Clinical trials | Reviews | Cell number | Interferon | Risk management | Heart diseases | Urine | Infections | FDA approval | Metabolism | Kinases | Patients | Skin cancer | Studies | Metabolites | Lymphocytes | Drug dosages | relapsing remitting multiple sclerosis
Journal Article